MetaCap

Immuneering (IMRX) vs Vanda Pharmaceuticals (VNDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vanda Pharmaceuticals (VNDA) has outperformed Immuneering (IMRX) over the past year, losing 28.2% versus a loss of 53.7%. Over five years, VNDA leads with a -79.2% price change compared with -85.0% for IMRX. Immuneering is the larger company by market cap ($218.9 million vs $208.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMRX-53.70%VNDA-28.23%
+107%+23%-61%
Nov 21, 20251 yearNov 20, 2026
IMRX-86.40%VNDA-79.69%
+11%-45%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMRX versus VNDA key metrics
MetricIMRXVNDA
Share price$3.38$3.45
Market cap$218.90M$208.32M
1-day change-2.03%-6.13%
YTD return-48.63%-60.94%
1-year return-53.70%-28.23%
5-year return-85.00%-79.18%
Forward P/E—17.22
EPS (TTM)$-0.92$-4.62
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$216.10M
Revenue growth (YoY)—+8.72%
Net income (latest FY)$-56.02M$-220.47M
Gross margin—93.96%
Operating margin—-69.95%
Net margin—-102.02%
52-week high$8.48$9.94
52-week low$3.29$3.42
Distance from 52-week high-60.14%-65.34%
Analyst consensusstrong_buynone
Avg. price target upside+402.96%+233.82%
Average volume747.66K1.06M
Shares outstanding64.76M60.47M
Employees65533
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VNDA has outperformed IMRX by 25.5 percentage points over the past year.

About Immuneering

IMRX stock →

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

About Vanda Pharmaceuticals

VNDA stock →

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.

Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees

IMRX vs VNDA FAQ

Which is bigger, Immuneering or Vanda Pharmaceuticals?

Immuneering (IMRX) is larger, with a market capitalization of $218.90M compared with $208.32M for Vanda Pharmaceuticals (VNDA).

Which stock has performed better over the past year, IMRX or VNDA?

VNDA returned -28.23% over the past 12 months, compared with -53.70% for IMRX (price return, excluding dividends). Past performance does not predict future results.

Are Immuneering and Vanda Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons